Clinical Trials

24 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05323955 2026-03-17

BRIDGET

Phase 1/2 Active not recruiting

48 enrolled

CNS

Brain Neoplasms

NCT04285671 2026-03-10

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07421141 2026-02-27

Opti-HER2

186 enrolled

Breast Neoplasms

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

28 enrolled

Phase NA Active not recruiting

Breast Neoplasms

NCT02226276 2026-02-13

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

10 enrolled 8 charts

Breast Neoplasms

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Breast Neoplasms

NCT02947685 2026-02-12

PATINA

518 enrolled 15 charts

Breast Neoplasms

NCT07407920 2026-02-12

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

120 enrolled

Phase 1/2 Active not recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT03368729 2026-01-23

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

46 enrolled

Phase 4 Active not recruiting

Breast Neoplasms

NCT04928261 2026-01-22

Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy

52 enrolled

Breast Neoplasms, Cardiotoxicity

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

53 enrolled 13 charts

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT04290793 2026-01-07

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

113 enrolled

Breast Neoplasms

NCT03199300 2025-12-11

InvestiCAT

Active not recruiting

20 enrolled

Tumor-Agnostic

Neoplasms, Second Primary

NCT03571633 2025-11-26

BREASTIMMU02

90 enrolled

HER2-positive Breast Cancer

NCT04193059 2025-11-26

PANSY

1,560 enrolled

Breast Neoplasms

NCT04733118 2025-11-20

PHERGAIN-2

393 enrolled

Breast Neoplasms

NCT01750073 2025-11-18

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

92 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04425018 2025-11-18

MARGOT

174 enrolled 19 charts

Breast Neoplasms

NCT05041842 2025-11-17

InTTercePT

53 enrolled

Metastatic Breast Cancer With a Isolated Brain Progression

NCT02827877 2025-11-14

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

18 enrolled 8 charts

Breast Neoplasms

NCT03738553 2025-10-29

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

Active not recruiting

13 enrolled

HER2-positive Breast Cancer

NCT00295893 2025-09-25

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

121 enrolled 10 charts

Phase 1 Active not recruiting

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT03716180 2025-09-22

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

100 enrolled

Breast Neoplasms

NCT04759248 2025-09-09

ATREZZO

55 enrolled

Breast Neoplasms, Neoplasms

NCT05063786 2025-09-08

ALPHABET

27 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

44 enrolled

Breast Diseases, Breast Neoplasms

NCT02436993 2025-07-14

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

120 enrolled

Breast Neoplasms

NCT03414658 2025-07-02

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

100 enrolled 15 charts

Breast Neoplasms

NCT01937117 2025-07-01

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

88 enrolled 15 charts

Breast Neoplasms

NCT03747120 2025-06-27

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]

138 enrolled 14 charts

Breast Neoplasms

NCT01273610 2025-06-10

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

40 enrolled 15 charts

Breast Neoplasms, Patient Compliance

NCT02678182 2025-06-10

PLATFORM

Phase 1 Active not recruiting

494 enrolled

Gastrointestinal

Adenocarcinoma of the Oesophagus

NCT00393783 2025-06-05

Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity

13 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT01730833 2025-06-03

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

63 enrolled 11 charts

Phase NA Active not recruiting

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT06190600 2025-04-30

SPORTNATHy

40 enrolled

Breast Neoplasms, Motor Activity

NCT03161353 2025-04-23

PHERGain

377 enrolled

Breast Neoplasms

NCT04296162 2025-04-17

ORCHID

178 enrolled

Breast Neoplasms

NCT03417544 2025-04-02

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

19 enrolled 26 charts

BreastCNS

HER2-positive Metastatic Breast Cancer

NCT00999804 2025-03-12

HELEX

128 enrolled 11 charts

Breast Neoplasms

NCT03820141 2025-03-10

DTP

39 enrolled

Breast Neoplasms

NCT02625441 2025-02-11

BOLD-1

516 enrolled

Breast Neoplasms

NCT03125928 2025-01-10

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

16 enrolled

Phase 2/3 Active not recruiting

HER2-positive Breast Cancer

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

136 enrolled

HER2-positive Breast Cancer

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT01996267 2024-03-29

TRAIN-2

437 enrolled

Breast Neoplasms

NCT03595592 2024-03-06

APTneo

650 enrolled

Invasive Breast Cancer

NCT04172259 2023-10-16

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

156 enrolled